Hypertrophic Clinical Trials

91 recruitingLast updated: June 15, 2026

There are 91 actively recruiting hypertrophic clinical trials across 39 countries. Studies span Not Applicable, Phase 2, Phase 4, Phase 3, Phase 1, Early Phase 1. Top locations include Beijing, Beijing Municipality, China, Boston, Massachusetts, United States, San Francisco, California, United States. Updated daily from ClinicalTrials.gov.


Hypertrophic Trials at a Glance

91 actively recruiting trials for hypertrophic are listed on ClinicalTrialsFinder across 6 cities in 39 countries. The largest study group is Not Applicable with 21 trials, with the heaviest enrollment activity in Beijing, Boston, and San Francisco. Lead sponsors running hypertrophic studies include Bristol-Myers Squibb, China National Center for Cardiovascular Diseases, and Shandong Suncadia Medicine Co., Ltd..

Browse hypertrophic trials by phase

Treatments under study

About Hypertrophic Clinical Trials

Looking for clinical trials for Hypertrophic? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hypertrophic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hypertrophic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 91 trials

Recruiting
Phase 3

LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.

Hypertrophic Cardiomyopathy (HCM)
Rennes University Hospital532 enrolled17 locationsNCT07202897
Recruiting

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb1,700 enrolled99 locationsNCT05489705
Recruiting
Phase 3

Topical Cryotherapy and Keloid/Hypertrophic Scars

hypertrophic scarsKeloid Scars
Sonal Choudhary30 enrolled1 locationNCT07336368
Recruiting

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Cardiac AmyloidosisCardiomyopathy, HypertrophicLumbar Spinal Stenosis+3 more
Columbia University1,663 enrolled6 locationsNCT06034405
Recruiting
Not Applicable

Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy

MastectomyGender DysphoriaHypertrophic scar
University of California, San Francisco78 enrolled1 locationNCT07147166
Recruiting
Not Applicable

Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial

Myocardial ischaemiaHypertrophic Obstructive Cardiomyopathy \(HOCM\)Left Ventricular Outflow Tract Obstruction
University of Manchester75 enrolled1 locationNCT07120776
Recruiting
Phase 2

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.165 enrolled67 locationsNCT07023614
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

Non-obstructive Hypertrophic CardiomyopathyObstructive Cardiomyopathy, Hypertrophic
Lexicon Pharmaceuticals500 enrolled108 locationsNCT06481891
Recruiting
Phase 4

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy (HCM)
Oregon Health and Science University40 enrolled2 locationsNCT07600177
Recruiting
Not Applicable

Exercise Prescription in Children With Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy Without Obstruction
Alder Hey Children's NHS Foundation Trust10 enrolled1 locationNCT07595354
Recruiting

A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China

Hypertrophic Cardiomyopathy
Bristol-Myers Squibb500 enrolled15 locationsNCT07361289
Recruiting

National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry

Sudden Cardiac DeathArrhythmogenic Right Ventricular DysplasiaCardiomyopathy, Dilated+11 more
Hospital do Coracao1,211 enrolled27 locationsNCT06546137
Recruiting

Multicentre Hypertrophic Cardiomyopathy Registry

Hypertrophic Cardiomyopathy (HCM)
University of Manchester2,500 enrolled1 locationNCT07381894
Recruiting

Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol-Myers Squibb362 enrolled1 locationNCT07557498
Recruiting
Phase 2Phase 3

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

PediatricSymptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics55 enrolled38 locationsNCT06412666
Recruiting
Phase 1Phase 2

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

Hypertrophic Cardiomyopathy
Tenaya Therapeutics30 enrolled10 locationsNCT05836259
Recruiting
Phase 2

Ademetionine in Obstructive Hypertrophic Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy (oHCM)
China National Center for Cardiovascular Diseases44 enrolled3 locationsNCT07367724
Recruiting

HCMR Re-Imaging Study

Hypertrophic Cardiomyopathy (HCM)
Christopher Kramer314 enrolled8 locationsNCT07054073
Recruiting
Phase 1Phase 2

Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases

TumorCardiovascular DiseasesPulmonary Fibrosis+3 more
Peking Union Medical College Hospital30 enrolled1 locationNCT07464132
Recruiting
Phase 4

A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)

Symptomatic Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb50 enrolled31 locationsNCT07004972